6 Undervalued Pharmaceuticals Stocks for Thursday, October 24
Discover the top 6 undervalued Pharmaceuticals stocks for Thursday, October 24 based on AAII’s Stock Grades.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Jack Gilleland
Jack Gilleland
Pratham Shah
Jenna Brashear
| Share Statistics | COCP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $18.8 | $433.9 | 11% |
|
| Shares Out (Mil) | 13.8 | 46.5 | 25% |
|
| Institutional Ownership | 19.7% | 82.2% | 9% |
|
| Float (Mil) | 14.6 | 47.7 | 24% |
|
| Beta | na | 0.74 | na |
|
| Avg Daily Volume (000s) | 31 | 345 | 25% |
|
| Price Change (52-week) |
(5.1%) | 52.0% | 46% |
|
| Growth | COCP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | 1.7% | (1.6%) | 42% |
|
| EPS (5yr) | 17.9% | 15.1% | 65 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.4%) | (15.1%) | 49% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 2 | 2 | |
| Current EPS | ($0.173) | ($0.725) | ($0.475) | |
| Month Ago EPS | ($0.173) | ($0.725) | ($0.475) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.175) | ($0.685) | ($0.640) | |
| Year/Year Chg | (24.5%) | (7.3%) | (19.4%) | |
| Financials | COCP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $289 | 0% |
|
| Net Income (TTM) (Mil) | ($10) | ($11) | 29% |
|
| EPS (TTM) | ($0.759) | ($0.600) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($7) | 22% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 17% |
|
| Enterprise Value (Q1) (Mil) | $18 | $331 | 11% |
|
| Valuation | COCP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 12.22 | 2.05 | 94% |
|
| P/E | na | 24.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | COCP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.9% | na |
|
| ROA | (151.1%) | (23.3%) | 3% |
|
| ROE | (311.7%) | (21.8%) | 2% |
|
| Liabilities to Assets | 77.5% | 31.2% | 73% |
|
| F-Score | 1 | 3 | 1% |
|
Cocrystal Pharma, Inc. did not pass any screens on 11/16/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors